key: cord-0830481-fhsiej9j
authors: Verma, R.; Kim, E.; Martinez-Colon, G. J.; Jagannathan, P.; Rustagi, A.; Parsonnet, J.; Bonilla, H.; Khosla, C.; Holubar, M.; Subramanian, A.; Singh, U.; Maldonado, Y.; Blish, C. A.; Andrews, J. R.
title: SARS-CoV-2 subgenomic RNA kinetics in longitudinal clinical samples
date: 2021-04-27
journal: nan
DOI: 10.1101/2021.04.26.21256131
sha: 62b62d0b2c50529d68aecb3445672ffa900042ac
doc_id: 830481
cord_uid: fhsiej9j

Abstract Background In light of numerous reports during the COVID-19 pandemic demonstrating an inexplicable persistence of viral RNA in clinically recovered patients, subgenomic RNAs (sgRNA) have recently been reported as potential molecular viability markers for SARS-CoV-2. However, few data are available on the longitudinal kinetics of sgRNA, compared with genomic RNA (gRNA), in clinical samples. Methods We analyzed 536 samples from 205 patients with COVID-19 from placebo-controlled, outpatient trials of Peginterferon Lambda-1a (Lambda; n=177) and favipiravir (n=359). Nasal swabs were collected at three time points in the Lambda (Day 1, 4 and 6) and favipiravir (Day 1, 5, and 10) trials. N-gene gRNA and sgRNA were quantified by RT-qPCR. To investigate the decay kinetics in vitro, we measured gRNA and sgRNA in A549ACE2+ cells infected with SARS-CoV-2, following treatment with remdesivir or DMSO control. Results At six days in the Lambda trial and ten days in Favipiravir trial, sgRNA remained detectable in 51.6% (32/62) and 49.5% (51/106) of the samples, respectively. Cycle threshold values for gRNA and sgRNA were highly linearly correlated (Pearsons r= 0.87) and the daily rate of increase did not differ significantly in Lambda (1.36 cycles/day vs 1.36 cycles/day; p = 0.97) or favipiravir (1.03 cycles/day vs 0.94 cycles/day; p=0.26) trials. From samples collected 15-21 days after symptom onset, sgRNA was detectable in 48.1% (40/83) of participants. In SARS-CoV-2 infected A549ACE2+ cells treated with remdesivir, the rate of Ct increase did not differ between gRNA and sgRNA. Conclusions In clinical samples and in vitro, sgRNA was highly correlated with gRNA and did not demonstrate different decay patterns to support its application as a molecular viability marker.

In clinical samples and in vitro, sgRNA was highly correlated with gRNA and did not 61 demonstrate different decay patterns to support its application as a viability marker. 62 63 64 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. as estimated from transmission studies appears much shorter than the duration of PCR positivity 69 in airway secretions (1,2). Studies comparing culture and RT-PCR from the same samples have 70 revealed that there is often substantial discrepancy between these measurements, with PCR 71 remaining positive for days to weeks longer than culture (3-7). While culture remains the 72 reference standard for detection of infectious virus, it may lack sensitivity, and it requires 73 biosafety level 3 facilities, precluding its use at scale as a clinical or public health tool (8). To 74 overcome this obstacle, there has been considerable interest in the development of molecular 75 viability markers to sensitively detect and quantify transcriptionally active virus (3, 9, 10) . 76 77 SARS-CoV-2 is an enveloped, positive sense, single-stranded RNA virus which employs a 78 complicated pattern of replication as well as transcription of genome length and smaller sgRNAs 79 (11). These sgRNAs are transcriptional intermediates, susceptible to enzymatic degradation, and 80

are not believed to be packaged in the final progeny virion, making them an attractive marker for 81 an actively transcribing virus (12). Small clinical studies have suggested that, compared with 82 gRNA, sgRNA correlates better with culturable virus. These studies targeted N-gene to detect 83 gRNA and compared sgRNA stability with a relatively less abundant/sensitive E-gene sgRNA 84 assay (2, 3, 9) . Despite the E-gene sgRNA assay possibly being suboptimal and may give false 85 negative results, these findings have led to the use of sgRNA assay as an outcome in preclinical 86 investigation of novel therapies (13,14) and its suggested use to terminate medical isolation for 87 6 individuals with COVID-19 (3). In contrast, a recent study found that sgRNAs were detectable 88 up to 17 days after initial detection and that they may be protected from nuclease degradation by 89 double membrane vesicles (15). However, because this study only had 12 clinical samples, 90 further evidence about the kinetics of sgRNA versus gRNA in longitudinal samples is needed to 91 determine whether sgRNA abundance better reflects recently transcribing viral infection. 92

Additionally, in order to serve as a marker of replicating virus, sgRNA is expected to show a 93 rapid decline after transcriptional inhibition due to ribonuclease degradation, in contrast to 94 gRNA, which may be protected from degradation by viral capsids and therefore persist more 95 durably (16). Therefore, we hypothesized that, upon treatment with SARS-CoV-2 RNA-96 dependent RNA polymerase inhibitors (17, 18, 19) in cell lines infected with SARS-CoV-2, we 97 should observe a rapid decline of sgRNA after viral death when compared with gRNA. 98 99 To address these gaps, we developed an N-gene sgRNA assay to directly compare its stability 100 with N-gene gRNA. sgRNAs in SARS-CoV-2 share a common leader sequence at the 5' end 101 which is absent in the gene amplified from the gRNA (9). We combined the common leader 102 sequence as forward primer with CDC N1 gene assay's reverse primer (20) to facilitate 103 comparison of N-gene sgRNA with gRNA copies. We applied this assay to serial samples from 104 individuals participating in two randomized clinical trials to characterize decay rates. 105

Additionally, we leveraged the inhibition of viral transcription and replication by an RNA-106 dependent RNA polymerase inhibitor (remdesivir) (19) to measure and compare the decay 107 kinetics of gRNA and sgRNA following polymerase inhibition in SARS-CoV-2 infected 108 A549 ACE2+ cells. 109 110 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) This was a sub-study of two Phase 2 randomized, placebo-controlled trials of peginterferon-118

Lambda-1a (Lambda) (NCT04331899) and favipiravir (NCT04346628) for treatment of 119 COVID-19. Individuals >18 years of age with RT-PCR confirmed SARS-CoV-2 infection were 120 recruited to participate and were eligible if they could be randomized within 72 hours of a 121 positive SARS-CoV-2 test and were not hospitalized. Additional exclusion criteria were 122 respiratory rate < 20 breaths per minute, room air oxygen saturation <94%, pregnancy or 123 breastfeeding, or use of other investigational agents for treatment of COVID-19. In the Lambda 124 trial, enrolled participants were randomized to a single injection with 180 mcg of Lambda versus 125 placebo injection and followed for 28 days. In the favipiravir trial, individuals were randomized 126 to oral favipiravir tablets (1800 mg on day 1, followed by 800 mg twice daily for 9 days) or 127 matching placebo. The primary outcome for both studies was time to cessation of viral shedding 128 as measured by qRT-PCR performed on oropharyngeal swab samples (Lambda trial) or nasal 129 swabs (favipiravir trial). In August 2020, we amended both protocols to collect nasal swabs (LH- were used for sgRNA amplification. We estimated copies/sample from a standard curve using a 156 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. derived from plasmids. Eukaryotic 18S rRNA commercial TaqMan assay (4333760T, Thermo 202

Fisher Scientific) was used as an internal control. 203 204

We estimated the change in cycle threshold (Ct) value for gRNA and sgRNA by day using 206 generalized linear mixed models with random effect for participant. We tested for differences in 207 the coefficients for collection day for outcomes of gRNA and sgRNA by performing ANOVA on 208 a joint model with a dummy variable for RNA type. We used generalized additive mixed models 209 with a random effect for participant to investigate the relationship between sample collection day 210 and cycle threshold (Ct) values. All analyses were performed using R (24). 211

We recruited 205 COVID-19 positive patients from placebo-controlled trials of interferon 215 Lambda (n=66) and Favipiravir (n=139) between August, 2020 and January, 2021. All 216 participants were enrolled in the trials within 72 hours of a positive SARS-CoV-2 RT-qPCR test. 217

Median age of the participants was 40 years (range, 18-73), and 46.8% (96/205) were female. 218

The majority of participants (197/205; 96.1%) reported one or more COVID-19 related 219 symptoms several days prior to enrollment (median, 5 days; range, 0-21). Symptoms with onset 220 more than three weeks prior to study enrollment were not considered to be associated with 221 COVID-19. The most common baseline symptoms reported by the patients before randomization 222 were cough, diarrhea, body ache, headache, fatigue and shortness of breath (Table 1) . 223 224 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. inside double membrane vesicles, which may protect viral genomic and subgenomic RNA from 289 cytoplasmic degradation due to host enzymes (29-33). We found that sgRNA and gRNA 290 increased at the same rate following infection of cells and then declined at the same rate 291 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) transcripts are less abundant than N-gene transcripts, so assays targeting them will have lower 301 analytical sensitivity (36). Indeed, we performed direct comparison of N-gene and E-gene assays 302 and found that the latter were approximately 5 Ct values higher for the same sample. There is not 303 clear premise to infer that E-gene transcripts are more rapidly degraded by ribonucleases or that 304 they better reflect recent transcription than N-gene sgRNAs. Negative-strand RNA detection in 305 SARS-CoV-2 has recently been reported as another potential viability marker (37). In a study by 306

Alexanderson and group, negative strand RNA was detected up to 11 days (15). However, 307 negative strand assays may be less analytically sensitive than sgRNA assays (37). This could 308 make them appear to be more specific, compared with culture, in clinical samples as they are 309 more likely to be negative when viral abundance is low. 310 311 Our study has several limitations, which include lack of viral culture data and samples at later 312 timepoints. Additionally, to study the sgRNA decay kinetics, we targeted a single and highly 313 abundant gene to compare and quantify gRNA and sgRNA, though we found high correlation 314 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21256131 doi: medRxiv preprint 16 between E-gene and N-gene sgRNA copy numbers. Analyzing additional targets would help us 315 understand the stability of other sgRNAs. Another limitation our study is lack of unblinded data 316 from the favipiravir study, precluding analysis by study arm. However, our findings of sgRNA 317 persistence in clinical samples and lack of difference in its decline compared with gRNA are 318 notable regardless of whether favipiravir reduced levels in one arm. For remdesivir, a RDRP 319 inhibitor like favipiravir, we found no differential effect on sgRNA, compared with gRNA, in 320 cell culture, despite effective reduction in viral replication and cytopathic effects. 321

In summary, we found that SARS-CoV-2 sgRNAs are persistently detectable in clinical samples, 323 correlate strongly with gRNA, and decline at indistinguishable rates in clinical samples and cell 324 culture. We find little evidence to support the premise that sgRNA detection is a reliable marker 325 of transcriptionally active virus or that it provides additional information beyond detection of 326 gRNA in clinical samples. We advise caution against using sgRNA assays to inform decisions 327 concerning treatment or medical isolation. 328 329 . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Clinical benefit of remdesivir in rhesus 377 macaques infected with SARS-CoV-2

Continuous and Discontinuous RNA Synthesis 379 in Coronaviruses

Subgenomic messenger RNA amplification in coronaviruses

Evaluation of the mRNA-1273 Vaccine against 383

SARS-CoV-2 in Nonhuman Primates

ChAdOx1 nCoV-19 vaccine prevents 385

SARS-CoV-2 pneumonia in rhesus macaques

SARS-CoV-2 genomic and subgenomic RNAs 387 in diagnostic samples are not an indicator of active replication

Cliver DO. Capsid and Infectivity in Virus Detection

Structural basis 393 for inhibition of the SARS-CoV-2 RNA polymerase by suramin